A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naive patients with progressive metastatic castration resistant prostate cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Sep 2018
At a glance
- Drugs Ipilimumab (Primary) ; Abiraterone acetate; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
- 07 Sep 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
- 31 Aug 2018 Biomarkers information updated